Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01550185 · ClinicalTrials.gov registry record · Phase 1
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01550185 is a Phase 1 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 10 participants.
The verdict
NCT01550185, a Phase 1 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to find out the highest safe dose and examine the side effects and effectiveness of eltrombopag olamine in patients with acute myeloid leukemia (AML) treated with chemotherapy that have not responded to previous therapy or have suffered a relapse
Interventions
- PROCEDURE standard follow-up care
- DRUG eltrombopag olamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-05 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01550185
The ClinicalTrials.gov registry entry for NCT01550185 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which standard follow-up care is the first listed.
NCT01550185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01550185 about?
NCT01550185 is a clinical study titled "Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia". The purpose of this study is to find out the highest safe dose and examine the side effects and effectiveness of eltrombopag olamine in patients with acute myeloid leukemia (AML) treated with chemotherapy that have not responded to previous therapy or have suffered a relapse
What is the current status of trial NCT01550185?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2012-05. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01550185?
The interventions under investigation include: standard follow-up care (PROCEDURE), eltrombopag olamine (DRUG).
Who is sponsoring clinical trial NCT01550185?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.